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Abstract 
Proadrenomedullin N-terminal 20 peptide (PAMP) is a candidate for a novel biologically active peptide processed from an adrenomedullin 
precursor. Using a radioimmunoassay for human PAMP, major and minor immunoreactive PAMPs were purified from porcine adrenal medulla 
and complete amino acid sequences were determined. The major immunoreactive peptide was PAMP itself with an amidated carboxy terminus. The 
minor one was determined to be PAMP[5-201. An intravenous bolus injection of human PAMP in anesthetized rats caused a rapid and strong 
hypotensive ffect in a dose dependent manner. The present data indicate that PAMP is an endogenous biologically active peptide which is processed 
from adrenomedullin precursor. 
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1. Introduction 
Adrenomedullin is a newly identified hypotensive pep- 
tide isolated from human pheochromocytoma. This 
novel peptide was discovered while monitoring the ele- 
vating activity of rat platelet CAMP [I]. Subsequently, 
cDNA clones encoding a human and a porcine adre- 
nomedullin precursor were isolated from human pheo- 
chromocytoma and from porcine adrenal medulla 
cDNA library and their nucleotide sequences were deter- 
mined [2,3]. The precursor for porcine adrenomedullin 
(preproadrenomedullin) consists of 188 amino acids in 
length, including the porcine adrenomedullin sequence. 
In addition to adrenomedullin, proadrenomedullin con- 
tains a unique 20 residue sequence followed by Gly-Lys- 
Arg in the N-terminal region. This peptide was termed 
proadrenomedullin N-terminal 20 peptide (PAMP) 
whose carboxy terminus may be amidated, although the 
biological activity of PAMP in vivo has not yet been 
explored. Very recently, we have established a radioim- 
munoassay (RIA) for human PAMP and examined im- 
munoreacive PAMP in human tissue [4]. Immunoreac- 
tive PAMP was abundant in the adrenal medulla and the 
cardiac atrium as well as in pheochromocytoma tissue. 
In the present study, using the RIA for human PAMP, 
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we purified immunoreactive PAMPs from porcine adre- 
nal medulla and determined their complete amino acid 
sequences. In the second part of the study, human PAMP 
was found to be a biologically active peptide which exerts 
a potent hypotensive activity in anesthetized rats. 
2. Materials and methods 
2. I. Peptides 
N-Tyr-human PAMP[l-ZO]NH, and human PAMP[l-20]NH,, -[I& 
20]NHz, and -[1620]COOH were synthesized by the solid phase method 
with a peptide synthesizer (43lA, Applied Biosystems), and purified by 
reverse-phase high performance liquid chromatography (HPLC). 
2.2. RIA for PAMP 
The RIA for human PAMP was performed by the method as de- 
scribed recently 141. The RIA incubation buffer for PAMP was 0.05 M 
sodium phosphate-buffer (pH 7.4), containing 0.5% bovine serum albu- 
min, 0.5% Triton X-100, 0.08 M NaCI, 0.025 M EDTA-2Na, 0.05% 
NaN, and 500 kIU/ml of aprotinin. The RIA incubation mixture was 
composed of 100 ~1 of standard PAMP or the unknown sample, and 
200 ~1 of antiserum at a dilution of 1:66,500 which contained 0.5% 
normal rabbit serum. After incubation for 12 h, 100 ~1 of ‘ZSI-labelled 
ligand (18,000 cpm) was added. After incubation for 24 h, 100 ~1 of 
anti-rabbit IgG goat serum diluent was added and incubated for 24 h. 
The tubes were centrifuged at 2,000 x g for 30 min, and radioactivity 
of the precipitate was measured by a gamma-counter (Aloka ARC-600, 
Tokyo). All assay procedures were performed in duplicate at 4°C. 
2.3. Preparation of peptide extract 
Preparation of peptide extract was performed by a method similar 
to that described [1,3]. Diced pieces of porcine adrenal medulla (5 g) 
were boiled for 10 min in 10 ~01s. of 1 M acetic acid containing 20 mM 
HCl to inactivate intrinsic proteases. After cooling, the mixture was 
homogenized at 4°C with a polytron homogenizer. The extract super- 
natant, obtained after 30 min centrifugation at 22,000 x g, was applied 
to a Sep-Pak C-18 cartridge column (20 ml, Waters). After washing the 
column with 0.1% trifluoroacetic acid (TFA), the materials adsorbed 
onto the column were eluted with 60% CH,CN containing 0.1% TFA. 
0014-5793/94/%7.00 0 1994 Federation of European Biochemical Societies. All rights reserved. 
SSDZ 0014-5793(94)00810-8 
36 K. Kitamura et al. I FEBS Letters 351 (1994) 35-37 
a ae loo- 
m 
E so- 
P 
I 
__-- 
__-- 
___--- 
___-- 
___--- 
1 I I I L 
0 20 40 Time (min) 
6( 1 
u 
- 60 
ae F I 40 _____--- ___--- B f 2 --- ____--- o 0 -__ _____- 
I I I I I 
0 20 40 
Time (min) 
6C 
Fig. 1. (a) Ion-exchange HPLC of porcine adrenal medulla monitored by RIA for human PAMP. Sample: Immunoreactive (ir-) PAMP obtained 
from 5 g porcine adrenal medulla tissue by gel filtration (Sephadex G-50). Column: TSK CM-ZSW, 4.0 x 300 mm. Flow rate: 1 ml/min. Solvent system: 
(A) 10 mM HCOONH, (pH 6.5): CH,CN = 90: 10 (by volume), (B) 1 M HCOONH, (pH 6.5): CH,CN = 90: 10 (by volume). Linear gradient elution 
from (A) to (B) for 60 min. Arrow indicates the elution position of synthetic human PAMP. Fig. 1 b: Reverse phase HPLC of porcine adrenal medulla 
monitored by RIA for human PAMP. Sample, The major immunoreactive fractions shown in Fig. la. Column: ODS 120A column (4.6 x 250 mm, 
Tosoh). Flow rate: 1.0 mUmin. Solvent system: linear gradient elution from A: B = 1OO:O to A:B = 0: 100 (60 min). (A) H,O: CH,CN: 10% TFA 
= 90: IO: 1 (by volume); (b)H,O:CH,CN: 10% TFA = 40:60: 1 (by volume). Arrow indicates the elution position of synthetic human PAMP. 
The eluate was concentrated, then was used as the starting material in 
the present study. 
2.4. Structural analyses 
Amino acid sequence analyses of the peptides were performed by a 
gas-phase sequencer equipped with phenylthiohydantoin amino acid 
analysing HPLC system (Model 470A/120A, Applied Biosystems). 
Phenylthiohydantoin amino acids were detectable as low as 0.1 pmol 
[51. 
2.5. Hypotensive effect 
Depressor effect of PAMP was examined by methods similar to those 
reuorted for human adrenomedullin 161. Seven-week-old male Wistar 
rats (300 g) were anesthetized by an &aperitoneal injection of pento- 
barbital sodium (50 mg/kg). Blood pressure was monitored continu- 
ously from a right carotid artery catheter (PE-50) connected to a 
Statham pressor transducer (mode1 P231D, Gould). A PE-IO catheter 
was inserted into the right jugular vein for administration of both 
maintenance solution and peptides. After equilibration for at least 60 
min, human PAMP was injected intravenously. 
3. Results and discussion 
We have already established a sensitive RIA system 
which can detect human PAMP [4]. Using this RIA sys- 
tem, we started purification of porcine PAMP from adre- 
nal medulla. Porcine adrenal medulla peptide extract, 
prepared as described in section 2, was separated by gel 
filtration chromatography (Sephadex G-50, fine, 
1.6 x 150 cm). One major ir-PAMP was observed in M, 
2000-2500. The peptides in the fraction were further 
separated by CM ion exchange HPLC on a column of 
TSK CM-2SW (4.0 x 150 mm, Tosoh). As shown in Fig. 
la, one major immunoreactive PAMP is observed at the 
same position as synthetic human PAMP, and two minor 
peaks emerge earlier. The major immunoreactive peak 
which contained more than 90% of total PAMP im- 
munoreactivity was further purified by reverse phase 
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Fig. 2. Reverse phase HPLC of a portion of purified porcine PAMP. 
Sample (a): I5 pmol of purified major immunoreactive PAMP as de- 
scribed in the text. Sample (b): 10 pmol of purified minor immunoreac- 
tive PAMP as described in the text. Column: y-Bondasphere ODS 300A 
(2.1 x 150 mm, Waters). Flow rate: 0.3 ml/min. Solvent system: linear 
gradient elution from A:B= 1OO:O to A:B=O:lOO (40 min). (A) 
H,O:CH,CN:lO%TFA=90:10:1 (by volume); (b) H,O:CH,CN: 
lO%TFA = 40:60: 1 (by volume). Absorbance at 210 nm (-) was 
monitored. Arrow indicates the elution position of synthetic human 
PAMP. 
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HPLC using an ODS 120A column (4.6 x 250 mm, 
Tosoh). As shown in Fig. lb, one major and one minor 
immunoreactive peaks were observed and they were fi- 
nally purified by reverse phase HPLC on Chemcosorb 
30DS-H column (4.0 x 150 mm, Chemco, Osaka). The 
recovery of major and minor peptides was 150 pmol and 
20 pmol, respectively, starting from 5 g of porcine adre- 
nal medulla. As shown in Fig. 2, reverse phase HPLC on 
a semimicro column of a portion of purified PAMPs 
gives a single peptide peak, confirming the homogeneity 
of these peptides. The major peak was eluted a little later 
than the synthetic human PAMP (Fig. 2a), while the 
minor immunoreactive peptide emerged 3.5 min earlier 
than that of human PAMP (Fig. 2b). 
Each purified peptide was subjected to a gas phase 
sequencer and complete amino acid sequences of major 
and minor immunoreactive peptides were determined as 
shown in Fig. 3. The major immunoreactive peptide was 
20-residue porcine PAMP itself, whose amino acid se- 
quence is identical to that of deduced amino acid se- 
quence by cDNA analysis. The carboxy-terminus of Arg 
was found to be amidated. The amino acid sequence of 
the minor immunoreactive peptide was found to be 
PAMP[5-201 which lacked four amino acids at the 
amino-terminal site of PAMP. Because the recovered 
amount of PAMP[5-201 is low compared to that of 
PAMP, PAMP[S-201 may be a mere metabolite of 
PAMP by proteolyses before extraction. But it cannot be 
denied at present hat PAMP[5-201 as well as PAMP has 
some biological function in vivo as an endogenous pep- 
tide. 
As a first step in investigating the biological activity 
of PAMP, we examined the vasodepressor effect of 
human PAMP, whose amino acid sequence was identical 
with that of porcine PAMP except for one amino acid 
residue. Human PAMP was found to elicit a potent hy- 
potensive effect in anesthetized rats. Typical hypotensive 
profiles for anesthetized rat are shown in Fig. 4. An 
intravenous bolus injection of PAMP caused a rapid and 
strong hypotensive effect in a dose dependent manner. 
When PAMP at 50 nmol/kg was injected intravenously, 
the maximum decrease of mean blood pressure was 
49 _+ 4.3 mmHg (mean f S.E.M., n = 6). This value is 
comparable to that of a 3 nmoYkg adrenomedullin injec- 
tion [I]. The significant hypotensive ffect lasted for 5-l 0 
Minor Immunoreactive PAMP 
“~1-*la-nla-clu-Phe-Arg-Zys-ly.-Trp-lsn-~_~~~ 
Fig. 3. Complete amino acid sequence of porcine PAMP. Sequence 
analysis was performed with major and minor immumoreactive 
PAMPs isolated from porcine adrenal medulla. 
37 
mmlig 
125 
I I I 
10 20 30 
Time (min) 
Fig. 4. Typical recordings for hypotensive responses in anesthetized rats 
to intravenous bolus injection of human PAMP. The maximum de- 
crease of mean blood pressure (mean +_ S.E.M., n = 6) was 9.0 +- 2.9 
mmHg for IO nmoVkg of PAMP, 33 + 5.3 mmHg for 20 nmoUkg of 
PAMP and 49 ? 4.3 mmHg for 50 nmollkg of PAMP 
min which was much shorter than that of adrenome- 
dullin [l]. Consequently, it was concluded that human 
PAMP has a potent hypotensive effect. Very recently, it 
has been reported that human PAMP had no hypoten- 
sive activity in anesthetized rats [7]. We cannot explain 
reasons for this discrepancy with our data, but our data 
have reproducibly demonstrated that human PAMP ex- 
erted hypotensive activity following their intravenous in- 
jections. 
In conclusion, we identified the porcine PAMP as an 
endogenous peptide and demonstrated for the first time 
that human PAMP had potent hypotensive activity. The 
present data indicate that PAMP as well as adrenome- 
dullin is biosynthesized from adrenomedullin precursor 
and may participate in circulation control. 
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